NASDAQ:SONN - Nasdaq - US83548R4020 - Common Stock - Currency: USD
NASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
The current stock price of SONN is 1.44 USD. In the past month the price decreased by -15.79%. In the past year, price decreased by -89.83%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Sonnet Biotherapeutics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540 US
CEO: Pankaj Mohan
Employees: 12
Company Website: https://www.sonnetbio.com/
Investor Relations: http://www.sonnetbio.com/investors
Phone: 16093752227
The current stock price of SONN is 1.44 USD. The price increased by 0.7% in the last trading session.
The exchange symbol of SONNET BIOTHERAPEUTICS HOLDI is SONN and it is listed on the Nasdaq exchange.
SONN stock is listed on the Nasdaq exchange.
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1316.67% is expected in the next year compared to the current price of 1.44. Check the SONNET BIOTHERAPEUTICS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SONNET BIOTHERAPEUTICS HOLDI (SONN) has a market capitalization of 4.39M USD. This makes SONN a Nano Cap stock.
SONNET BIOTHERAPEUTICS HOLDI (SONN) currently has 12 employees.
SONNET BIOTHERAPEUTICS HOLDI (SONN) has a resistance level at 1.6. Check the full technical report for a detailed analysis of SONN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SONN does not pay a dividend.
SONNET BIOTHERAPEUTICS HOLDI (SONN) will report earnings on 2025-05-12.
SONNET BIOTHERAPEUTICS HOLDI (SONN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.43).
The outstanding short interest for SONNET BIOTHERAPEUTICS HOLDI (SONN) is 3.85% of its float. Check the ownership tab for more information on the SONN short interest.
Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -10.43. The EPS increased by 89.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -268.39% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to SONN. The Buy consensus is the average rating of analysts ratings from 7 analysts.